• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吉米沙星与克拉霉素对不同喹诺酮敏感性肺炎链球菌的血清杀菌活性

Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.

作者信息

Malerczyk C, Kolbert M, Kinzig-Schippers M, Sörgel F, Machka K, Shah P M

机构信息

Institut für Pharmakologie, Philipps Universität, D-35033 Marburg, Germany.

出版信息

J Chemother. 2004 Feb;16(1):56-61. doi: 10.1179/joc.2004.16.1.56.

DOI:10.1179/joc.2004.16.1.56
PMID:15078000
Abstract

The objective of this study was to determine serum bactericidal titers (SBT, the highest dilution of serum showing no growth) and the serum bactericidal activity (SBA, i.e. duration of SBT greater than 1:2) as well as the serum bactericidal rate of gemifloxacin and clarithromycin after single doses in healthy male volunteers against Streptococcus pneumoniae. Strains tested had various degrees of susceptibility to penicillin as well as different susceptibility to quinolones due to a different QRDR mutation pattern (parC, gyrA). Serum samples from volunteers (n = 12) who had received a single oral dose of either 320 mg gemifloxacin or 500 mg clarithromycin in an open-label crossover study were obtained over a 24-hour period. SBA was determined, using the microdilution method. SBA of wildtype strains for gemifloxacin ranged from 8.9 to 15.4 h (mean 12.6 h). For gemifloxacin, 2 strains with solitary gyrA mutation had an SBA from 4.5 to 4.7 h (median 4.5 h). One of the 2 strains with a single QRDR mutation in parC displayed an SBA of 4.5 h, comparable to the gyrA mutation strains, whereas the second strain had a nearly twice as long SBA of 8.9 h. Two strains with two mutations (parC and gyrA) did not display any SBA. For clarithromycin, the duration of SBA ranged from 11.3 to 15.5 h (mean 13.6 h) for 6 of the 12 strains with an MIC < or = 0.06 mg/L (no SBA was found for the remaining strains, with an MIC of 0.25 mg/L or higher). In conclusion, a correlation between individual serum concentrations and SBA was found for both antibiotics.

摘要

本研究的目的是测定健康男性志愿者单次服用吉米沙星和克拉霉素后对肺炎链球菌的血清杀菌滴度(SBT,即血清中无细菌生长的最高稀释度)、血清杀菌活性(SBA,即SBT大于1:2的持续时间)以及血清杀菌率。由于喹诺酮耐药决定区(QRDR)突变模式(parC、gyrA)不同,所测试的菌株对青霉素有不同程度的敏感性,对喹诺酮类药物也有不同的敏感性。在一项开放标签交叉研究中,从接受单次口服320 mg吉米沙星或500 mg克拉霉素的志愿者(n = 12)中获取24小时内的血清样本。采用微量稀释法测定SBA。吉米沙星野生型菌株的SBA范围为8.9至15.4小时(平均12.6小时)。对于吉米沙星,2株具有孤立gyrA突变的菌株的SBA为4.5至4.7小时(中位数4.5小时)。在parC中有单个QRDR突变的2株菌株中的1株显示SBA为4.5小时,与gyrA突变菌株相当,而第二株菌株的SBA几乎是其两倍,为8.9小时。2株具有两个突变(parC和gyrA)的菌株未显示任何SBA。对于克拉霉素,12株中6株MIC≤0.06 mg/L的菌株的SBA持续时间为11.3至15.5小时(平均13.6小时)(其余MIC为0.25 mg/L或更高的菌株未发现SBA)。总之,两种抗生素的个体血清浓度与SBA之间均存在相关性。

相似文献

1
Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.吉米沙星与克拉霉素对不同喹诺酮敏感性肺炎链球菌的血清杀菌活性
J Chemother. 2004 Feb;16(1):56-61. doi: 10.1179/joc.2004.16.1.56.
2
Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.吉米沙星在体外及小鼠肺炎模型中对喹诺酮耐药肺炎链球菌菌株的活性。
Antimicrob Agents Chemother. 2005 Mar;49(3):1046-54. doi: 10.1128/AAC.49.3.1046-1054.2005.
3
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.吉米沙星与其他九种药物的抗肺炎球菌活性比较。
Antimicrob Agents Chemother. 2000 Feb;44(2):304-10. doi: 10.1128/AAC.44.2.304-310.2000.
4
Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of Streptococcus pneumoniae.缓释克拉霉素对肺炎链球菌大环内酯类耐药菌株的血清杀菌活性
Pharmacotherapy. 2002 May;22(5):593-6. doi: 10.1592/phco.22.8.593.33214.
5
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.加雷沙星(BMS-284756)与其他六种喹诺酮类药物相比,对肺炎链球菌、草绿色链球菌和粪肠球菌的体外活性。
Antimicrob Agents Chemother. 2003 Nov;47(11):3542-7. doi: 10.1128/AAC.47.11.3542-3547.2003.
6
Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.在台湾,吉米沙星可以部分克服具有 gyrA 突变的幽门螺旋杆菌的喹诺酮类药物耐药性。
Helicobacter. 2012 Jun;17(3):210-5. doi: 10.1111/j.1523-5378.2012.00935.x. Epub 2012 Mar 20.
7
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.在脓毒症小鼠模型中,采用全或无死亡率终点指标测定吉米沙星、莫西沙星和左氧氟沙星对携带gyrA和parC点突变肺炎球菌的体内活性。
Int J Antimicrob Agents. 2005 Feb;25(2):163-7. doi: 10.1016/j.ijantimicag.2004.08.017.
8
[Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].西他沙星及其他新型喹诺酮类药物对耐抗菌药物肺炎链球菌的杀菌活性
Jpn J Antibiot. 2013 Feb;66(1):25-35.
9
Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.吉米沙星与八种氟喹诺酮类药物对肺炎链球菌的抗菌活性及已发表的药效学比较。
Int J Antimicrob Agents. 2005 Jul;26(1):81-4. doi: 10.1016/j.ijantimicag.2005.03.004.
10
Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
J Infect Chemother. 2006 Feb;12(1):1-8. doi: 10.1007/s10156-005-0420-0.

引用本文的文献

1
Bactericidal Activity of Serum by RB51 Outer Membrane Protein's Combined by S99 Lipopolysaccharide Induction.RB51外膜蛋白与S99脂多糖诱导结合后血清的杀菌活性
Avicenna J Med Biotechnol. 2024 Jul-Sep;16(3):187-192. doi: 10.18502/ajmb.v16i3.15745.